Buy Cjc-1295 Without Dac Online

Sourcing CJC-1295 Without DAC for Laboratory Research

To buy CJC-1295 Without DAC online for institutional research, investigators must source from certified domestic suppliers providing lot-specific HPLC and Mass Spectrometry documentation. CJC-1295 Without DAC is a 29-amino-acid tetrasubstituted peptide GHRH analog evaluated in preclinical models for sustaining pulsatile growth hormone (GH) and downstream IGF-1 expression during tissue repair and metabolic research.

When procuring CJC-1295 Without DAC for in vitro assays or animal models, raw chemical purity dictates experimental accuracy. Impurities introduced during solid-phase peptide synthesis (SPPS)—such as truncated sequences, deletion peptides, or residual TFA salts—can alter receptor binding kinetics and yield non-reproducible data. Researchers must demand transparent quality control standards, including third-party ISO 17025 laboratory verification for every production lot.

PX1 Research supplies high-purity research peptides synthesized in GMP-compliant, USA-based facilities. Every batch undergoes rigorous purity testing to ensure that institutional facilities receive pure, endotoxin-verified compounds suitable for demanding physiological and biochemical studies.

Molecular Structure and Pharmacodynamics of Modified GRF 1-29

CJC-1295 Without DAC is chemically designated as Modified GRF 1-29 (Growth Hormone-Releasing Factor). The native endogenous GHRH peptide consists of 44 amino acids, though its biological activity resides primarily within the N-terminal 1–29 sequence (sermorelin). However, native GHRH 1-29 is rapidly degraded in biological matrices by the enzyme dipeptidyl peptidase IV (DPP-IV), resulting in a circulatory half-life of less than 12 minutes in mammalian models.

To enhance metabolic stability without altering physiological binding mechanisms, peptide chemists introduced four specific amino acid substitutions into the GRF 1-29 backbone: D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27. These specific structural modifications render the peptide resistant to enzymatic cleavage by DPP-IV, extending its terminal elimination half-life to approximately 30 minutes in preclinical animal studies.

Unlike formulations bound to a Drug Affinity Complex (DAC), CJC-1295 Without DAC does not covalently bind to circulating serum albumin. As a result, it exhibits a shorter, transient kinetic profile that mimics endogenous, pulsatile GHRH signaling rather than continuous, tonic receptor activation. This distinct pharmacokinetic profile makes it a crucial tool for laboratory investigations focused on natural endocrine rhythms.

Preclinical Research Applications: GH Pulse Secretion and IGF-1 Expression

In preclinical research models, CJC-1295 Without DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) located on anterior pituitary somatotrophs. Binding initiates a intracellular signal transduction cascade mediated by Gs alpha protein coupling, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. This cascade triggers both the immediate exocytosis of stored growth hormone vesicles and the upregulation of GH gene transcription.

Because CJC-1295 Without DAC lacks the albumin-binding lysine-linker complex found in DAC variants, somatotroph GHRH receptors experience intermittent activation rather than prolonged desensitization. Preclinical rodent models demonstrate that administration of Modified GRF 1-29 produces discrete pulses of GH release, preserving the natural somatostatinergic feedback loop. Downstream, elevated GH circulating levels stimulate hepatic synthesis of Insulin-like Growth Factor 1 (IGF-1), a primary mediator of cellular proliferation, protein translation, and nitrogen retention.

Laboratory investigations utilize CJC-1295 Without DAC to study musculoskeletal repair kinetics, collagen synthesis in extracellular matrix models, tendon fibroblast proliferation, and metabolic substrate oxidation. Researchers exploring the broader endocrine cascade frequently consult our research library for comparative literature on GHRH receptor signaling pathways.

Comparative Analysis: CJC-1295 Without DAC vs. Related Secretagogues

When designing peptide protocols, researchers frequently compare CJC-1295 Without DAC against other secretagogues in its class. Understanding structural and operational differences ensures the selection of the correct compound for specific experimental endpoints.

The primary distinction between Modified GRF 1-29 and CJC-1295 With DAC lies in the presence of the Maleimidoproprionyl carboxyl group attached to the C-terminus of the DAC variant. While CJC-1295 With DAC creates a permanent covalent bond with serum albumin—extending its half-life to 6–8 days—CJC-1295 Without DAC exhibits a ~30-minute half-life, allowing researchers to control exact pulse timing. Compared to early-generation Sermorelin, CJC-1295 Without DAC provides superior enzymatic resistance against DPP-IV degradation due to its tetrasubstituted amino acid sequence.

In many experimental models, GHRH analogs are co-evaluated with Growth Hormone Secretagogue Receptor (GHSR-1a) agonists such as Ipamorelin. While GHRH analogs activate the cAMP pathway via GHRHR, GHSR agonists trigger intracellular calcium influx via the phospholipase C pathway. In vitro assays demonstrate a synergistic release of growth hormone when both pathways are stimulated simultaneously without inducing hypercortisolemia or prolactin elevation. For detailed structural comparisons, examine our deep dive on GHRH analogs and mechanism kinetics.

Analytical Purity Verification and ISO 17025 Quality Standards

The scientific validity of any preclinical trial depends on chemical identity and purity. When you buy CJC-1295 Without DAC online for institutional use, evaluating the supplier's analytical documentation is a mandatory step in chemical procurement.

High-Performance Liquid Chromatography (RP-HPLC) is utilized to measure chemical purity by separating the target peptide from synthesis side-products, diastereomers, and short-chain impurities. PX1 Research mandates a minimum purity threshold of >99% for all research peptides. Accompanying HPLC chromatograms display clear peak separation and integration data verifying minimal background signal.

Mass Spectrometry (ESI-MS or MALDI-TOF) confirms molecular weight and chemical identity. The theoretical monoisotopic mass of CJC-1295 Without DAC (C152H252N44O42) is approximately 3367.9 Da. Mass spectrometry reports must show a dominant mass peak matching this exact molecular weight, ensuring no sequence mutations occurred during synthesis.

Furthermore, bacterial endotoxin testing (Limulus Amebocyte Lysate assay) is critical for cell culture viability and in vivo rodent safety. PX1 Research enforces strict endotoxin limits (<0.1 EU/mg) across all lots, ensuring that biological response data remains unconfounded by lipopolysaccharide-induced inflammatory responses.

Reconstitution, Handling, and Laboratory Storage Protocols

CJC-1295 Without DAC is supplied as a sterile, lyophilized (freeze-dried) white cake or powder sealed in glass vials under inert gas. Proper handling procedures must be observed to prevent peptide oxidation, hydrolysis, or mechanical shear stress.

For laboratory reconstitution, researchers should use bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution depending on the requirements of the downstream assay. The reconstituting solvent should be gently introduced along the glass inner wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle swirl agitation should be used; vigorous shaking must be avoided to prevent protein denaturing and aggregation.

Lyophilized CJC-1295 Without DAC remains stable at -20°C for up to 24 months, or at -80°C for extended archival storage. Once reconstituted into liquid solution, the peptide should be kept refrigerated at 2°C to 8°C and utilized within 21 to 28 days to prevent chemical degradation. Multiple freeze-thaw cycles must be strictly avoided, as thermal fluctuations break peptide bonds and reduce active molar concentration.

Verifying Domestic USA Manufacturing and Supplier Integrity

Peptide procurement managers face significant risks when sourcing materials from unverified overseas vendors. Foreign manufacturers frequently operate without oversight, resulting in batch-to-batch variation, residual solvent contamination (such as piperidine or acetonitrile), and inaccurate labeling of DAC vs. Non-DAC variants.

PX1 Research operates exclusively with GMP-compliant, USA-based synthesis facilities. Domestic production ensures strict adherence to quality management systems, complete raw material traceability, and immediate chain-of-custody oversight. Every lot is assigned a unique tracking number linked to its specific Certificate of Analysis (COA).

Orders fulfilled through PX1 Research ship directly from our state-of-the-art distribution centers in California and Arizona. We offer same-day shipping for orders placed Monday through Friday before cut-off times, ensuring your laboratory maintains uninterrupted research timelines without inventory delays.

Institutional Procurement and Lab Account Setup

PX1 Research supports academic institutions, biotechnology firms, contract research organizations (CROs), and independent laboratories with streamlined purchasing pipelines. We accommodate single-vial evaluation orders as well as large-scale bulk manufacturing runs for multi-phase study designs.

Institutional buyers requiring volume purchasing, custom synthesis concentrations, or dedicated lot reservation can establish a wholesale lab account. Our technical sales team provides full chain-of-custody documentation, safety data sheets (SDS), and dedicated account management to ensure compliance with institutional procurement standards.